| Issue Size | ₹138.99 CrTotal Consideration |
|---|---|
| Market Cap | ₹1,405.97 CrPharma Sector |
| Issue Price | ₹1,522.85Per Equity Share |
| RSI | 83.34Overbought Zone |
Key highlights
- Preferential allotment of up to 9,12,759 equity shares approved by the Board
- Issue price fixed at ₹1,522.85 per share for a total consideration of ₹138.99 crore
- Participation from 15 non-promoter investors including WhiteOak Capital and Aurum Rising India Fund
- Proceeds earmarked for equity or loan-based investments in company subsidiaries
- Extraordinary General Meeting scheduled for October 23, 2026, to seek shareholder approval
The Fundraise Mechanism
Bharat Parenterals is utilizing a preferential allotment route to issue 9,12,759 fully paid-up equity shares of face value ₹10 each. Priced at ₹1,522.85 per share, the issuance targets a select group of 15 non-promoter investors, encompassing Alternative Investment Funds (AIFs), Foreign Portfolio Investors (FPIs), and individual entities. The pricing reflects a structured entry for new capital, with the WhiteOak Capital India Opportunities Fund emerging as the largest participant in this round, slated to hold a 3.87% post-issue stake.
The board meeting finalized these terms on September 29, 2026, ahead of an Extraordinary General Meeting convened for late October.
Strategic Use of Proceeds
- Undertaking fresh equity investments in existing and new subsidiary projects
- Providing quasi-equity or unsecured loans to facilitate subsidiary-level development
- Enhancing liquidity for the execution of long-term pharmaceutical expansion plans
- Strengthening the consolidated balance sheet to support infrastructure development
- Accelerating project timelines across various therapeutic segments within the group
Business and Operations Overview
Bharat Parenterals is a WHO-GMP certified pharmaceutical manufacturer headquartered in Vadodara, Gujarat. The company specializes in a wide array of dosage forms, including tablets, capsules, liquid orals, ointments, and specialized injectable facilities. Operating as a recognized Star Export House, it maintains a robust manufacturing infrastructure for both beta-lactam and non-beta-lactam products.
The firm leverages its research and development capabilities to offer contract manufacturing services and branded generic formulations to both domestic and international markets, positioning itself as a diversified player in the pharmaceuticals and biotechnology sector.
Financial and Industry Context
The pharmaceutical sector is seeing increased institutional interest in mid-sized manufacturing entities with export capabilities. Bharat Parenterals currently carries a market capitalization of ₹1,405.97 crore and has demonstrated high momentum with a one-year return of 65.18%. While the company reported a net loss for the trailing twelve months, the entry of sophisticated institutional investors like WhiteOak Capital and Aurum Rising India Fund signals confidence in its project pipeline.
The current issue price of ₹1,522.85 is positioned relative to a 30-day Simple Moving Average (SMA) of ₹1,528.1, indicating the fundraise is occurring during a period of significant stock price consolidation.
| Share price | ₹2040 |
|---|---|
| Market capitalisation | ₹1,405.97 Cr |
| Revenue (annual) | ₹345.43 |
| Net profit (annual) | ₹-8.19 |
| P/E (TTM) | -91.28×Sector 49.7× |
| Promoter holding | 67.2%+0.03% QoQ |
| FII holding | 0.11%Current quarter |
Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.
Exchange filing by Bharat Parenterals Limited announcing the board's approval for a preferential allotment of equity shares to raise ₹139 crore. Market figures from a third-party data provider.
Track Bharat Parenterals live
Get the next Bharat Parenterals filing on Telegram seconds after it lands. 15 days free.
